{"entity":{"id":"nct04042701","kind":"trial","name":"Trastuzumab deruxtecan with pembrolizumab","aka":["DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer"],"tldr":"This early study combines trastuzumab deruxtecan with pembrolizumab in advanced breast or lung cancer. It studies a suitable dose, side effects and tumor response.","summary":"This early study combines trastuzumab deruxtecan with pembrolizumab in advanced breast or lung cancer. It studies a suitable dose, side effects and tumor response.\n\nInterventional study registered as NCT04042701, sponsored by Daiichi Sankyo. Registry phase: 1. Registry enrollment is 115 participants (estimated). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT04042701","url":"https://clinicaltrials.gov/study/NCT04042701"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT04042701"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","trastuzumab-deruxtecan"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04042701","phase":"1","setting":"Locally advanced or metastatic breast cancer or non-small cell lung cancer","sponsor":"Daiichi Sankyo","participation":[{"nct":"NCT04042701","source":"https://clinicaltrials.gov/study/NCT04042701","fetchedAt":"2026-10-10T20:54:21.083546Z","studySha256":"dcb479beba343b06fc2d122b269a27623cb4af0cc6693a5061c4967aa510d013","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-11-18","leadSponsor":"Daiichi Sankyo","collaboratorCount":2,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":115,"enrolmentType":"ESTIMATED","siteCount":30,"recruitingSiteCount":0,"countries":["France","Spain","United Kingdom","United States"]}],"started":"2020-02-10","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04042701/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}